Nicolás Meyer
471 works · 15,131 citations · h-index 44
Top works
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
- Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
- CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals
- 1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
- Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis
- High endothelial venules (HEVs) in human melanoma lesions
- Psoriasis: an epidemiological evaluation of disease burden in 590 patients
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial